Skip to main content

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2019

GUILFORD, Conn. -- Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended November 30, 2019. All are available under the Company’s profile on SEDAR at www.sedar.com and on the Company’s website at www.bioasis.us/investors/. Read More

from Financial Post https://ift.tt/2RAuk6i
Labels:

Comments

Post a Comment

Popular posts from this blog

With Trump’s WeChat ban approaching, here are several alternatives

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . WeChat, China’s most popular app, faces an imminent ban in the U.S. , leaving many of its users in a bind. The White House said Friday it would prohibit WeChat , owned by Beijing-based Tencent, from appearing in U.S. app stores starting Sunday at midnight.  Though WeChat has a comparatively minor U.S. presence, it remains a major conduit for communications between Chinese nationals living abroad and their friends and family back home . The app has an average of 19 million million daily active users in the U.S. versus more than a billion worldwide.  WeChat, called Weixin in China, is effectively the operating system for people’s digital lives in China. They use it to pay for services, hail cabs, go shopping, read news, chat, and more. For people seeking to bridge the digital divide between the U.S. and China, WeChat is not easily re...
Post a Comment
Read more